We are glad and very proud to be among the TOP50 start-up in which to invest in 2018 selected by the prestigious swiss economic newspaper Bilan. Every year, the magazine Bilan selects 50 of the most promising StartUps in Switzerland. A jury made up of innovation professionals selects Swiss nuggets, in fields as varied as fintech, biotech, medtech,…

Nagi Bioscience is featured today in the Swiss newspaper Le Temps. This article (in French) discusses the current problematic of animal testing in the scientific research and highlight the solution developed by Nagi Bioscience. You can read the article online here or on the today’s paper version of the journal in the science section. Good reading!

From tomorrow morning till Friday evening, Nagi Bioscience will attend the Hello Tomorrow Summit in Paris as one of the World’s TOP500 Deep-Tech Startups. We are glad to be one of the startups selected for a showcase of our technology during this event. Come to visit us at booth #14 on Friday morning and see our “show”…

We are delighted to announce that our team will pitch the technology developed by Nagi Bioscience during the ILMAC Lausanne exhibition on Thursday, the 5th of October. The first-ever edition of ILMAC LAUSANNE is taking place on October 4 and 5, as the unique exhibition platform for the chemistry and life science community in the French-speaking part of…

From September 10th to 13th, Nagi Bioscience attended the 53rd Congress of the European Societies of Toxicology (EuroTox) in Bratislava. Our team presented for the first time a poster with the latest results obtained in collaboration with Debiopharm SA.

We are delighted to announce that Nagi Bioscience has been chosen by Hello Tomorrow as one of the world’s TOP 500 deep-tech startups! Hello Tomorrow is a global not-for-profit organization created by deep tech entrepreneurs, with a mission to empower and connect the most promising deep-tech entreprises across the globe to accelerate the transfer of breakthrough technologies into real world solutions. Come…

We are happy to announce the release of a new publication in collaboration with the Laboratory of Prof. Robin Gasser from the University of Melbourne. The article issued today in the FASEB Journal shows that deguelin, a plant-derived rotenoid, selectively and potently inhibits motility and development of nematodes, which supports its potential as a lead candidate for drug development as new anthelmintic…

In 2015, the project developed by Nagi Bioscience was the first recipient of the SGV 25th Fund.  This fund was created by the SGV board to financially support projects related to the goals of the SGV, that are promotion of the Laboratory Animal Science and the Animal Welfare, and ethical considerations in animal experimentation. Read more about the…

Our Business Plan was awarded as TOP 10, among 108 submitted projects! »Venture» is Switzerland’s premier startup competition, initiative of  ETH Zurich, EPF Lausanne, Knecht Holding, the innovation promotion agency CTI and McKinsey & Company, Switzerland.

This prestigious prize is given annually by the “E. Naef Foundation for in vitro research” (FENRIV), established in 1998. The foundation assists researchers investigating scientific means for restricting the use of vivisection and generally promotes in vitro research. Our team has been awarded for its work on the development of a novel in vitro technology for testing the toxicity of chemical compounds…